This newly created leadership role will be instrumental in navigating the development and commercialization of grounding breaking drugs in the gene editing/CRISPR space. Responsibilities include process development for DP & substance, analytical, formulations, QA/QC, and global supply chain.
34 resumes submitted
28 candidate interviews
A transformative genome editing company with a mission to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level. CRISPR is a complex biologic molecule which can be developed as a drug in many different formats.
Martin Caney, Managing Partner at Engage, specializes in presenting candidates within Drug Development to help facilitate company growth, commercialization of products, and to assist with career development. Martin has been responsible for numerous successful placements ranging from Chief Technical Officer to Scientist level opportunities throughout North America. He can be reached at email@example.com.